Результаты поиска - Márk Barok

  • Отображение 1 - 10 результаты of 10
Отмена результатов
  1. 1
    Trastuzumab emtansine: mechanisms of action and drug resistance

    Trastuzumab emtansine: mechanisms of action and drug resistance по Márk Barok, Heikki Joensuu, Jorma Isola

    Опубликовано 2014
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  2. 2
    Die hard: Are cancer stem cells the Bruce Willises of tumor biology?

    Die hard: Are cancer stem cells the Bruce Willises of tumor biology? по Ákos Fábián, Márk Barok, György Vereb, János Szöllősi

    Опубликовано 2008
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  3. 3
    Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo

    Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo по Márk Barok, Minna Tanner, Katri Köninki, Jorma Isola

    Опубликовано 2011
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  4. 4
    Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation

    Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation по Márk Barok, Maija Puhka, György Vereb, János Szöllősi, Jorma Isola, Heikki Joensuu

    Опубликовано 2018
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  5. 5
    Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer

    Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer по Zsuzsanna Pályi‐Krekk, Márk Barok, Jorma Isola, Markku Tammi, János Szöllo ̋si, Péter Nagy

    Опубликовано 2007
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  6. 6
    A Novel Anti-HER2 Antibody–Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine

    A Novel Anti-HER2 Antibody–Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine по Vadim Le Joncour, Ana Martins, Maija Puhka, Jorma Isola, Marko Salmikangas, Pirjo Laakkonen, Heikki Joensuu, Márk Barok

    Опубликовано 2019
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  7. 7
    Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model

    Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model по Negar Pourjamal, Narjes Yazdi, A. Halme, Vadim Le Joncour, Pirjo Laakkonen, Pipsa Saharinen, Heikki Joensuu, Márk Barok

    Опубликовано 2024
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  8. 8
    Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan

    Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan по Negar Pourjamal, Vadim Le Joncour, György Vereb, Cilla Honkamäki, Jorma Isola, Jeffrey V. Leyton, Pirjo Laakkonen, Heikki Joensuu, Márk Barok

    Опубликовано 2025
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  9. 9
    EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis

    EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis по Zsuzsa Rákosy, Laura Vízkeleti, Szilvia Ecsedi, Zoltán Vokó, Ágnes Bégány, Márk Barok, Zsuzsa Krekk, Mónika Gallai, Zoltán Szentirmay, Róza Ádány, Margit Balázs

    Опубликовано 2007
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  10. 10
    Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance

    Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance по Márk Barok, Jorma Isola, Zsuzsanna Pályi‐Krekk, Péter Nagy, István Juhász, György Vereb, Päivikki Kauraniemi, Anita Kapanen, Minna Tanner, György Vereb, János Szöllősi

    Опубликовано 2007
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: